Regulatory Briefings: FDA's "Internal Advisory Committees"
This article was originally published in RPM Report
When FDA reviewers need help on a tricky regulatory question, they get advice from top-level officials at an internal meeting called a regulatory briefing. Many sponsors don't even know they exist. But at a time of change in review procedures and staff, companies need to learn how FDA's "internal advisory committees" work.
You may also be interested in...
With Zurampic, FDA Again Made Do With Sorry State Of Regulatory Science In Gout
Zurampic, which AstraZeneca licensed to Ironwood, pushed the limits of FDA's tolerance of the regulatory compromises agency has had to make in gout; our Drug Review Profile shows how statistician's case against approval received serious consideration, although the agency ultimately valued consistency with previous approvals in the space.
A Question Of Identity: Drug & Botanical Perspectives On Manufacturing Clash In Fulyzaq Review
Salix’ botanical product Fulyzaq tested the limits of the conventional small molecule chemistry approach to ensuring the identity of drug substance. After a regulatory briefing with CDER Director Woodcock, the botanicals and CMC review teams agreed on a bioassay to bridge the gap in their regulatory perspectives.
Long Term Commitments: Novo Breaks New Ground with Victoza.
The Victoza approval took longer than Novo hoped. But the review time looks like nothing compared to the post-marketing monitoring the company will be required to do.